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Abstract
Background: This meta-analysis aims to provide more evidence on the role of postoperative chemoradiotherapy
(CRT) for gastric cancer (GC) patients in Asian countries where D2 lymphadenectomy is prevalent.
Methods: We conducted a systematic review of randomized controlled trials (RCTs), extracted data of survival and
toxicities, and pooled data to evaluate the efficacy and toxicities of CRT compared with chemotherapy (CT) after D2
lymphadenectomy.
Results: A total of 960 patients from four RCTs were selected. The results showed that postoperative CRT significantly
reduced loco-regional recurrence rate (LRRR: RR = 0.50, 95 % CI = 0.34–0.74, P = 0.0005) and improved disease-free
survival (DFS: HR = 0.73, 95 % CI = 0.60–0.89, P = 0.002). However, CRT did not affect distant metastasis rate (DMR: RR = 0.
81, 95 % CI = 0.60–1.08, P = 0.15) and overall survival (OS: HR = 0.91, 95 % CI = 0.74–1.11, P = 0.34). The main grade 3–4
toxicities manifested no significant differences between the two groups.
Conclusions: Overall, CRT after D2 lymphadenectomy may reduce LRRR and prolong DFS. The role of postoperative
CRT should be further investigated in the population with high risk of loco-regional recurrence.
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Background
Despite its decline in the incidence over the past cen-
tury, gastric cancer (GC) remains the second leading
cause of cancer-related mortality worldwide and the
most prevalent cancer in East Asia [1]. Surgical resection
is considered the primary curative approach for this dis-
ease. However, even after radical resection, the loco-
regional recurrence rate (LRRR) currently ranges from
24 % to 54 % [2], indicating that the effectiveness of sur-
gery alone remains poor and unsatisfactory. Due to the
high risk of loco-regional recurrence (LRR), issues about
the extent of lymph node dissection and multimodality
treatment have always been discussed.
During the past two decades, combined modality ther-
apy has been widely investigated to prevent recurrence
and improve survival for GC patients after curative re-
section. Due to the lack of powerful evidence regarding
which of the current multimodality treatment is more
beneficial, the standards of the postoperative and pre-
operative treatments differ around the world.
Perioperative chemotherapy (CT) (the MAGIC [3] and
FFCD9703 [4] trials) and postoperative chemoradiother-
apy (CRT) (the INT-0116 [5] trial) are recommended for
resectable GC in Europe and North America, respect-
ively. In Asian countries, postoperative CT is considered
as the standard treatment based on the results of the
ACTS-GC [6] and CLASSIC [7] trials.
D2 lymphadenectomy has been widely accepted in
Asian countries, whereas two randomized controlled tri-
als (RCTs) (the Dutch [8–10] and MRC [11, 12] trials) in
the West did not demonstrate significant survival
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advantage of D2 lymphadenectomy over D1. Currently,
D2 lymphadenectomy is recommended in Western
countries if it is performed by well-trained surgeons with
acceptable rates of postoperative mortality [13]. How-
ever, the INT0116 trial was initiated in 1991 and 90 % of
patients received D0 or D1 lymphadenectomy in this
trial. This was considered to be sub-optimal and thus, it
cannot be arbitrarily used for reference in Asian coun-
tries, where D2 lymphadenectomy is widely performed.
After curative resection with D2 lymphadenectomy
and postoperative CT, about 10 % of patients will still
have LRR [6]. Therefore, it is meaningful to explore
whether radiotherapy (RT) added to postoperative CT
will further improve survival for GC patients after D2
curative resection. Only a few small prospective studies
[14–16] and retrospective studies [17–22] have explored
the role of postoperative CRT, but the results were in-
consistent. Previously published meta-analyses [23–29]
seldom included D2 lymph node dissection in their se-
lection criteria. The team who conducted the ARTIST
trial updated its follow-up results and for the first time
reported the data of OS in their article published in
2015 [30]. Therefore, we conducted this meta-analysis
based on the latest survival data, aiming to provide more
evidence for this issue.
Methods
Literature search strategy
A systematic review of eligible RCTs was performed by
searching the electronic databases, which consist of
PubMed, EMBASE, Cochrane Library, and Web of Sci-
ence. The keywords used for search were as follows:
“gastric cancer,” “stomach neoplasms,” “chemoradiother-
apy,” “combined modality therapy,” and “D2”. Search
strategy was slightly adjusted according to the require-
ment of different databases. The search was limited to
RCTs which were reported in English only. The deadline
of this search was June 1, 2015. We also searched the
annual meeting proceedings of ASCO, ESMO, and
ASTRO. In addition, reference lists of systematic reviews
and selected trials were scanned for any other possible
relevant trials.
Selection of trials
Two reviewers (Meng-long Zhou and Mei Kang) inde-
pendently assessed every retrieved study for inclusion.
All RCTs that compared CRT with CT in postoperative
treatment for R0 resected GC with D2 lymphadenec-
tomy were included in this meta-analysis. However, a
preoperative CT or CRT is not allowed. When multiple
publications by the same team from the same institution
were found, the article that provided the most complete
follow-up data on survival was selected.
Quality assessment
Cochrane Collaboration’s tool was used for assessing risk
of bias of RCTs (RoB tool, 5.1.0) [31]. RoB tool included
the following index: sequence generation, allocation con-
cealment, blinding of participants, personnel and out-
come assessors, incomplete outcome data, selective
outcome reporting, and other sources of bias. In all
cases, an answer “Yes” indicated a low risk of bias, an
answer “No” indicated high risk of bias, and if insuffi-
cient detail was reported of what happened in the study,
the judgment would usually be “Unclear” risk of bias.
Data extraction
The same two reviewers independently reviewed eligible
studies for baseline characteristics and clinical relevance.
Disagreements were resolved by an independent third
reviewer (Gui-chao Li). The following variables were ex-
tracted from each trial onto standardized data collection
forms if available: author, research title, year of publica-
tion, numbers of patients in each arm, baseline charac-
teristics (age, sex, ECOG performance status, primary
tumor site, Lauren classification, tumor stage), treatment
(CT regimens, RT dose and technique, treatment com-
pletion), endpoints, length of follow-up, toxicities, and
deaths.
Statistical analysis
Survival variables were defined as generic inverse vari-
ance data. Hazard ratio (HR) and 95 % confidence inter-
val (CI) for DFS and OS were extracted directly from
the original article if possible. When HR and 95 % CI
were not reported, they were calculated from published
summary statistics or estimated from Kaplan-Meier sur-
vival curves using Tierney method [32]. Results regard-
ing dichotomous data, such as loco-regional recurrence,
distant metastasis, and toxicities, were reported as risk
ratio (RR) with 95 % CI. The significance of the pooled
data was determined by the Z-test, and a P value of less
than 0.05 was considered as statistically significant.
Statistical heterogeneity between studies was examined
using the chi-square-based Q-test and also expressed as I2.
A P value of more than 0.10 for the Q-test and I2 of less
than 50 % indicated a lack of heterogeneity across the tri-
als. If there was no statistically significant heterogeneity in
a given set of data, the fixed effects model was used.
Otherwise, the random effects model was used. However,
due to the fixed effects model tended to underestimate
standard errors of pooled estimates, random effects model
was used for the quantitative pooling [31, 33].
Publication bias was estimated by visually assessing the
asymmetry of funnel plot. Furthermore, Egger’s test was
also performed to provide quantitative evidence of publi-
cation bias [34]. A P value of less than 0.05 was considered
representative of statistically significant publication bias.
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Sensitivity analysis was performed by sequentially omitting
individual study to check the stability of the result. The
statistical tests for our meta-analysis were performed with
RevMan software (version 5.3, Cochrane).
Results
Trial flow and characteristics
Finally, four RCTs met the inclusion criteria of this
study. The included studies were published between
2010 and 2015 with the number of the enrolled patients
ranging from 61 to 458. A total of 960 patients from
four RCTs [14–16, 30] were identified for this meta-
analysis at last. All studies were conducted in Asia (three
[14, 15, 35] in Korea and one [16] in China). Two of
them [15, 30] used AP-PA fields as a part of concurrent
CRT, one [14] used three-dimensional conformal radio-
therapy (3D-CRT) and one [16] applied intensity-
modulated radiotherapy (IMRT). Two RCTs [14, 30]
used cisplatin combined with capecitabine or fluoroura-
cil as the CT regimens, and another two RCTs [15, 16]
used the same CT regimen as that of the INT0116 trial.
The PRISMA flow diagram of studies is shown in Fig. 1.
Characteristics of the studies are summarized in Table 1.
Quality assessment
Four RCTs were evaluated [14–16, 30, 35]: overall qual-
ities were acceptable, and the baseline characteristics of
patients were all reported. All RCTs mentioned “ran-
dom", but none of them reported the details about
random sequence generation which describes the
method used to generate the allocation sequence in
sufficient detail to allow an assessment of whether it
should produce comparable groups. No RCT reported
adequate allocation concealment which describes the
method used to conceal the allocation sequence in
sufficient detail to determine whether intervention
Fig. 1 Flow chart of the study selection process
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allocations could have been foreseen in advance of, or
during, enrolment. All RCTs were with low risks of
incomplete outcome data. One RCT was with high
risk of reporting bias due to its undetailed report of
toxicities [15]. Blind method was not mentioned in all
trials; however, this should unlikely affect the quality
assessment results (Fig. 2).
Patients’ survival data
From four RCTs, 960 randomized patients, 493 in
the CRT group and 467 in the CT group, were in-
cluded in the meta-analyses of DFS and OS. The re-
sult of the test for heterogeneity of the treatment
effects were non-significant (DFS: P = 0.96, I2 = 0 %;
OS, P = 0.58, I2 = 0 %). Compared with CT, CRT
Table 1 Characteristics of the included RCTs
References Kwon et al. [14] Kim et al. [15] Zhu et al. [16] ARTIST 2012/2015
Characteristics CRT CT CRT CT CRT CT CRT CT
Patient number 31 30 46 44 186 165 230 228
Age year 56 (23–73) 49 (29–70) >60, (19.6 %) >60, (31.8 %) 56 (38–73) 59 (42–75) 56 (28–76) 56 (22–77)
Sex no. (%)
Male 21 (67.7) 23 (76.7) 34 (73.9) 25 (56.8) 135 (72.9) 126 (76.4) 143 (62.2) 153 (67.1)
Female 10 (32.3) 7 (23.3) 12 (26.1) 19 (43.2) 51 (27.1) 39 (23.6) 87 (37.8) 75 (32.9)
ECOG PS no. (%)
0 NR NR 35 (76.1) 27 (61.4) NR NR 99 (43.0) 96 (42.1)
1 NR NR 11 (23.9) 17 (38.6) NR NR 131 (57.0) 132 (57.9)
Primary tumor site no. (%)
Proximal 6 (16.1) 4 (13.3) 3 (6.5) 2 (4.5) 30 (16.1) 15 (9.1) 13 (5.7) 9 (3.9)
Body 9 (29.0) 11 (36.7) 26 (56.5) 19 (43.2) 21 (11.3) 33 (20) 107 (46.5) 112 (49.1)
Antrum 17 (54.8) 15 (50.0) 14 (30.5) 18 (40.9) 135 (72.6) 117 (70.9) 90 (39.1) 87 (38.2)
Multiple/diffuse 0 0 3 (6.5) 5 (11.4) 0 0 20 (8.7) 20 (8.8)
Laurén’s classification no. (%)
Intestinal 5 (16.1) 12 (40.0) 16 (34.8) 15 (34.1) NR NR 75 (32.6) 88 (38.6)
Diffuse 20 (64.4) 13 (43.3) 26 (56.5) 24 (54.5) NR NR 144 (62.6) 130 (57.0)
Mixed/unclassified 6 (19.4) 5 (16.7) 4 (8.6) 5 (11.3) NR NR 11 (4.8) 10 (4.4)
Tumor stage no. (%)
Ib 0 0 0 0 20 (10.8) 15 (9.1) 49 (21.3) 50 (21.9)
II 0 0 0 0 36 (19.4) 30 (18.2) 84 (36.5) 86 (37.7)
III 24 (77.4) 27 (90.0) 34 (73.9) 31 (75.0) 103 (55.4) 96 (58.2) 71 (30.8) 65 (28.6)
IV (M0) 7 (22.6) 3 (10) 12 (26.1) 11 (25.0) 27 (14.5) 24 (14.5) 26 (11.3) 27 (11.8)
pN+ NR NR 46 (100) 42 (95.5) 158 (84.9) 143 (86.7) 203 (88.2) 193 (84.6)
Lymphadenectomy D2 D2 D2 D2
Treatment regimens FP/RT FP FL/RT FL FL/IMRT FL XP/XRT/XP XP
Total RT dose/technique 45 Gy/3D-CRT 45 Gy/AP-PA fields 45 Gy/IMRT 45 Gy/AP-PA fields
Endpoints 3-ys DFS: 80.0 % vs 75.2 %;
P = 0.887
5-ys DFS: 76.7 % vs 59.1 %;
P = 0.222
5-ys OS: 70.1 % vs 70.0 %;
P = 0.814
5-ys DFS: 60.9 % vs 50.0 %;
P = 0.246
5-ys OS: 65.2 % vs 54.6 %;
P = 0.67
5-ys RFS: 45.2 % vs 35.8 %,
P = 0.029
5-ys OS: 48.4 % vs 41.8 %,
P = 0.122
3-ys DFS: 78.2 % vs 74.2 %;
P = 0.0862
7-ys DFS: P = 0.740
5-ys OS: 75 % vs 73 %;
P = 0.484
Median follow-up months 77.2 (24–92.8) 86.7 (60.3–116.5) 42.5 2012: 53.2(36.9–77.3)
2015: 7 years
FP regimen: 5-Fu 1000 mg/m2 continuous infusion on days 1–5, cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; FP/RT: 1 cycle of FP, then RT (45 Gy
of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 3 cycles of FP;
FL regimen: 5-Fu 425 mg/m2, leucovorin 20 mg/m2, for 5 days with a 4-week interval, totally 5 cycles; FL/RT: 1 cycle of FL, then RT (45 Gy of radiation at 1.8 Gy
per day, 5 days per week, for 5 weeks with 2 cycles of FL), followed by 2 cycles of FL; XP regimen: capecitabine 1000 mg/m2 twice daily on days 1 to 14; cisplatin
60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; XP/XRT/XP: 2 cycles of XP, then XRT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with
continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 2 cycles of XP
CT chemotherapy, CRT chemoradiotherapy, NR not reported, 3-ys DFS 3-year disease-free survival, 5-ys DFS 5-year disease-free survival, 5-ys OS 5-year overall
survival, 3D-CRT 3D conformal radiotherapy, IMRT intensity-modulated radiotherapy, LN lymph node
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significantly improved DFS (HR = 0.73, 95 % CI 0.60–
0.89, P = 0.002). However, postoperative CRT did not
have a significant positive effect on OS (HR = 0.91,
95 % CI 0.74–1.11, P = 0.34). The detailed data is
shown in Fig. 3.
Loco-regional recurrence and distant metastasis
Local-regional recurrence was reported in four studies,
and the results of the meta-analysis indicated that there
was a significant difference in LRRR between the two
groups (RR = 0.50, 95 % CI 0.34–0.74, P = 0.0005) (Fig. 4).
Fig. 2 a Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies. b Risk of
bias summary: review authors’ judgments about each risk of bias item for each included study
Fig. 3 Forest plot of comparison: D2, R0 resection followed by postoperative chemoradiotherapy (CRT) versus D2, R0 resection followed by
postoperative chemotherapy (CT). Outcomes: 1.1.1 DFS is significantly improved. 1.1.2 OS is not significantly improved
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As for the distant metastasis rate (DMR), no significant
difference was found between the two groups in our
meta-analysis (RR = 0.81, 95 % CI 0.60–1.08, P = 0.15).
Toxicities
Table 2 shows the main grade 3–4 toxicities occurred in
each study. One trial [35] used common terminology
criteria for adverse events (CTCAE version 2.0) to evalu-
ate toxicities, another [16] used CTCAE version 3.0,
while the other two trials [14, 15] did not mention the
toxicity scale used. Differences among trials in the extent
and methods of evaluation make statistical pooling of
toxicities data impossible. Therefore, we only conducted
a descriptive comparison from the available data. Gener-
ally, there were no significant differences in grade 3–4
toxicities between postoperative CRT and CT groups in
three of the four trials [15, 16, 35]. However, Kwon et al.
reported a higher rate of grades 3 and 4 neutropenia
(48.4 %) with postoperative CRT than CT (16.7 %) [14].
Publication bias assessment
According to Cochrane Handbook for Systematic Re-
views of Interventions [31], tests for funnel plot asym-
metry should be used only when there are at least ten
studies included in the meta-analysis; because when
there are fewer studies, the power of the tests is too low
to distinguish chance from real asymmetry. Therefore,
the funnel plot was not given in this meta-analysis which
included only four RCTs.
Fig. 4 Forest plot of comparison: D2, R0 resection followed by postoperative chemoradiotherapy (CRT) versus D2, R0 resection followed by postoperative
chemotherapy (CT). Outcomes: 2.1.1 Loco-regional recurrence (LRR) is significantly decreased. 2.1.2 Distant metastasis (DM) is not significantly decreased
Table 2 Main grade 3–4 toxicities of the included RCTs
References Kwon et al. [14] Kim et al. [15] Zhu et al. [16] ARTIST 2012/2015
Characteristics CRT CT CRT CT CRT CT CRT CT
Patient number 31 30 46 44 186 165 230 228
Nausea/vomiting 2 (6.5) 4 (13.3) NR NR 8 (4.3) 0 35 (15.4) 36 (15.9)
Diarrhea 1 (3.2) 0 NR NR 3 (1.6) 0 2 (0.9) 5 (2.2)
Neutropenia 15 (48.4) 5 (16.7) NR NR 14 (7.5) 12 (7.3) 110 (48.4) 92 (40.7)
Anemia 4 (12.9) 5 (16.7) NR NR 0 0 1 (0.4) 4 (1.7)
Thrombocytopenia NR NR NR NR 0 0 2 (0.9) 0
Criteria NR NR CTCEA 3.0 CTCEA 2.0
Numbers in the brackets refer to percentages
CRT chemoradiotherapy, CT chemotherapy, NR not reported
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Sensitivity analyses
Sensitivity analyses were performed to evaluate whether
the pooled estimates of DFS, OS, LRRR, and DMR were
different by exclusion of the highest weighted study and
by omitting the RCTs that only included stage III/IV GC
in each pooled analysis. Finally, the results were stable
and all consistent with the above outcomes.
Discussion
Main findings
GC is a heterogeneous malignancy with poor prognosis
and diverse treatment patterns globally [36]. Surgery is
accepted as the primary treatment but the outcome re-
mains dismal [37]. In Asian countries, several RCTs [7,
38] and meta-analyses [39, 40] have proven the efficacy
of postoperative CT. In North America, the INT-0116
trial demonstrated the efficacy of postoperative CRT
compared with surgery alone for the treatment of resect-
able GC. An observational study from Korea implies that
postoperative CRT can prolong survival and decrease re-
currence compared with observation after D2 surgery
[18]. Additionally, several retrospective studies [20–22,
41] about postoperative CRT have been reported. How-
ever, all the abovementioned studies cannot settle the
issue raised in our meta-analysis, that is, will postopera-
tive CRT further improve survival compared with post-
operative CT after R0 gastrectomy with D2
lymphadenectomy. Relevant RCTs [14–16, 30] are
scarce, and controversy still exists. The ARTIST trial,
which was designed to settle this issue, yielded negative
results. However, given the default limitations in its trial
design, the role of postoperative CRT after D2 dissection
remains undefined. Thus, we performed an up-to-date
meta-analysis, which summarized all the valuable data of
the existing RCTs, aiming to provide more powerful re-
sults directing standard treatment for GC.
The present study showed that postoperative CRT,
compared with postoperative CT, can improve LRRR
and DFS, but did not improve DMR and OS. The benefit
brought by CRT has not transformed into a better OS
and a series of plausible reasons for this interesting find-
ing are as follows: first, distant metastasis (DM) is the
predominant recurrence pattern after D2 lymphadenec-
tomy in the Asian population [42]. In contrast, LRR was
more frequent than DM in the Western population who
underwent D2 gastrectomy [43]. Second, D2 lymphade-
nectomy produces more reduction of LRR than that of
DM, which can be supported by the results of the Dutch
Gastric Cancer Group Trial [9] and the Taiwanese trial
[44]. Moreover, postoperative CRT, as a local treatment
alike to D2 lymphadenectomy, does not reduce DM even
compared with observation [5, 18, 45]. Therefore, Huang
et al. [23] maintained that the DM might offset the loco-
regional control brought by CRT for Asian patients
underwent D2 gastrectomy. Indeed, we can observe in
these four RCTS that the DMR is higher than LRRR
(16.1–37.0 vs. 4.8–15.6 %). Huang et al. considered that
a high percentage of diffuse-type GC, which is prone to
early metastasis, is the reasons why DM is the predom-
inant recurrence pattern in the Asian population [46].
Around 60 % of patients in three of the four RCTs in-
cluded in our meta-analysis were diffuse-type GC. This
is also parallel with the result of a meta-analysis which
reported that there is a significantly higher percentage of
diffuse-type GC in the Asian population, which
accounted for more than 50 % [47]. However, this ex-
planation is inconsistent with the results of a RCT which
proved that postoperative RT was effective to patients
with diffuse-type GC [48]. Therefore, this controversy,
which is raised by the INT-0116 trial decades ago, is still
not well settled up to now.
In the ARTIST trial, patients with stage Ib and II GC
accounted for nearly 60 % in both arms. Fan et al. con-
sidered that patients in relatively early stages with a
lower risk of LRR in the study may dilute the survival
benefit of CRT [49]. However, Dai et al. gave an opposite
explanation of why improved loco-regional control has
not transferred to OS benefit. They considered that pa-
tients with stages III–IV (M0) took a big proportion
which is no less than 60 %, and the prognosis was still
poor for patients at an advanced stage even if LRR was
controlled since the lymph node metastasis occurred
more frequently and the nutritional status was worse
[28]. In addition to TNM stage, status of lymph nodes is
associated with the efficacy of CRT. According to the
subgroup analysis of the ARTIST trial, patients with
positive lymph nodes could benefit from postoperative
CRT. A retrospective study by Costa et al. also came to
the same conclusion [21]. Inconsistently, although al-
most all patients in the trial conducted by Kim et al. [18]
had positive lymph nodes (pN+, 100 % in the CRT group
and 95.5 % in the CT group), it did not produce signifi-
cantly improved DFS and OS. This may possibly ascribe
to the small sample size, which was smaller than the es-
timated one and decreased the likelihood of finding a
significant difference between the two groups. However,
this is only our assumption, and we hope the ongoing
ARTIST II trial could answer this question [50].
At present, we should not arbitrarily negate the effect
of CRT after D2 dissection. It may be important and
worthwhile to select patients at high risk of recurrence
who would benefit from postoperative CRT. The ART-
IST II trial [50] and another trial [51] conducted in
China may better define the role of postoperative CRT
in GC treated with D2 lymphadenectomy as they both
focus on patients with stages II–III (according to the 7th
AJCC staging system) disease and positive lymph nodes
(pN+), and limit the surgery type to D2 lymph node
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dissection. These two trials are still enrolling patients,
and we are looking forward to their preliminary results.
Yu et al. [52] analyzed the results of the ARTIST trial,
precisely defined the recurrent sites and found that post-
operative CRT after D2 resection in GC reduced regional
recurrence, especially in group 3 lymph nodes. However,
no difference was observed between the two arms re-
garding the local recurrence, which may ascribe to that
the remnant stomach was not considered a routine RT
target in the present study. Therefore, for all the patients
with positive lymph nodes, they can also be further
stratified by the sites of involved lymph nodes and more
prospective studies are required to evaluate the optimal
RT target.
Limitations
First, only four eligible trials were selected and this pos-
sibly could not unveil the real situation. Second, baseline
characteristics of patients were similar among selected
trials, except for tumor stage. Patients with stages III
and IV (M0) were included in two selected trials (Kwon
et al. [14] and Kim et al. [15] trials), but stage Ib–IV GC
was included in Zhu et al. [16] and the ARTIST trial.
However, sensitivity analyses showed that the results of
meta-analysis are stable. Third, the RT techniques applied
were different, including conventional AP-PA fields, 3D-
CRT, and IMRT. Additionally, CT regimens differed.
Compared with the present commonly used XELOX (oxa-
liplatin plus capectabine) or SOX (oxaliplatin plus S-1)
regimens, the cytotoxic drugs used in the included RCTs
may have relatively low efficacy with high toxicities.
Fourth, the Kwon et al. [14] trial has high risk of reporting
bias. Generally, regarding these limitations mentioned
above, results should be cautiously interpreted.
Conclusions
In sum, postoperative CRT after D2 surgery may benefit
loco-regional control and improve DFS. However, it can-
not bring survival benefit in an unselected group of pa-
tients. The role of postoperative CRT should be further
investigated in the population with high risk of LRR.
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